Boston Scientific announced that the FDA has approved its Renegade HI-FLO Fathom Pre-Loaded system for selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature. The system will primarily be used by interventional radiologists for minimally invasive procedures to treat uterine fibroids and liver cancer.
“The excellent deliverability, torque transmission and flow capacity of the Renegade HI-FLO Fathom Pre-Loaded system provides physicians with the performance they need to efficiently access tortuous vessels across many types of interventional oncology procedures,” said Jeff Geschwind, director of Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine, Maryland, USA. “Having the Fathom-16 Guidewire pre-loaded in the Renegade HI-FLO Microcatheter will reduce my procedural preparation time and the number of devices that my staff must manage.”
The Renegade HI-FLO Fathom Pre-Loaded system combines the turn-for-turn torque response, flexibility and high visibility of the Fathom-16 Steerable Guidewire with the clinically proven performance of the Renegade HI-FLO Microcatheter, pre-loaded in a single convenient platform. The system will be available in eight configurations to suit a broad range of peripheral embolization procedures.
“Adding the pre-loaded system to our product offerings demonstrates Boston Scientific’s commitment to providing a comprehensive suite of less-invasive solutions for interventional radiologists and their patients,” said Joe Fitzgerald, senior vice president and president of Boston Scientific’s Endovascular Unit. “We will continue to bring additional technologies to market that advance the various therapies performed by specialists in vascular and interventional radiology.”
